RFCA
TGTX icon

R&F Capital Advisors’s TG Therapeutics TGTX Stock Holding History

R&F Capital Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		$136K Sell
11,701
-3,609
-24% -$25.9K 0.04% 597
2016
Q4 		$71K Buy
+15,310
New +$89.8K 0.03% 462

Other funds holding TGTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BM
Bridger Management New York $150M AUM 17.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

R&F Capital Advisors's TGTX Position: Q1 2017 in Review

R&F Capital Advisors reduced its TG Therapeutics (TGTX) stake by 24% in Q1 2017, selling an estimated $25.9K and leaving 11,701 shares worth $136K. The position accounts for 0.04% of the portfolio, ranked #597.

R&F Capital Advisors first reported a position in TGTX in Q4 2016 and has held it in 2 quarters since. 97 funds tracked by Wall St. Rank hold TGTX as of Q1 2017.

  • R&F Capital Advisors held 11,701 shares of TG Therapeutics worth $136K as of Q1 2017.
  • R&F Capital Advisors sold 3,609 TG Therapeutics shares in Q1 2017, an estimated $25.9K.
  • TG Therapeutics made up 0.04% of R&F Capital Advisors's portfolio in Q1 2017, its #597 holding.
  • R&F Capital Advisors first reported a position in TG Therapeutics in Q4 2016 and has held it in 2 quarters since.
  • 97 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2017.

Based on R&F Capital Advisors's 13F filing for Q1 2017, filed 15 May 2017.